Keytruda

Gilead’s Trodelvy approved for triple-negative breast cancer in Europe

While patients whose tumours express PD-L1 can receive immunotherapies like Merck/MSD’s Keytruda (pembrolizumab), advanced TNBC remains a very difficult cancer to treat.

Merck receives first breast cancer approval in Europe for Keytruda

Merck’s anti-PD-1 therapy, Keytruda, is approved in the Europe Union for certain patients with triple-negative breast cancer plus chemotherapy. ... Patients in all 27 European Union member states plus Iceland, Lichtenstein, Norway and Northern Ireland

FDA approves Seagen/Genmab’s antibody-drug conjugate Tivdak for women with advanced cervical cancer

Also, two clinical trials involving combination therapies – involving both Tivdak and Merck’s Keytruda – have shown encouraging results. ... New data is also available on first-line treatment for cervical cancer involving Merck’s megablockbuster

Tecentriq withdrawn in hard-to-treat breast cancer in US

In July, the FDA gave full approval to Keytruda in both advanced/metastatic and in early-stage TNBC. ... However, with Keytruda fully approved for the indication, the FDA no longer “considers it appropriate” to maintain the accelerated approval, said

Merck’s Keytruda gains two more approvals in Japan

Keytruda, an anti-programmed death receptor-1 (PD-1) therapy, increased the ability of the immune system to detect and fight tumour cells. ... Keytruda is approved in a huge range of oncology indications across the world.

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]